Presentation of interim analysis from approximately 25 six-month evaluable BCG-Unresponsive patients in the ongoing ADVANCED-2 trial expected at a medical...
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients...
Revenue Increased 128% Year Over Year and 48% SequentiallyFORT MILL, S.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc....
MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective health Jupiter, Florida, Aug. 11,...
Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically...
TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company")...
Appointment recognizes Mr. Durso’s extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH Mitchel Sayare,...
USPTO Issues Patent No. US 12,343,315 B2 covering topical cannabinoid compositions for clear skin TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE)...
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage...
New site established in collaboration with a government agency to bolster spider silk output and market readinessANN ARBOR, Mich., Aug....
JUPITER, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $400.0...
Successful completion of strategic reorganization, reducing debt by $1.15 billion.In connection with emergence on 6/24/25, fiscal Q2 consists of a...
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray,...
Novel PARG inhibitor FORX-428 has shown best-in-class characteristics in preclinical studiesTrial initially taking place in the U.S., following IND clearanceInitial...
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1...
– Global, pivotal Phase 3 study will evaluate efficacy and safety of zorevunersen compared to sham over a 52-week treatment...
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like...
Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially...
Initiated a second potentially registrational study of IMVT-1402 in Graves’ disease (GD) and a potentially registrational study of IMVT-1402 in...
BASEL, Switzerland and LONDON and NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial...